Investment Considerations
- Nutriband’s proprietary AVERSA™ technology addresses a critical need in the opioid crisis by deterring abuse of transdermal medications.
- The company’s lead product, the AVERSA™ Fentanyl Transdermal System, is progressing through the regulatory pathway with the potential to enhance the safety profile of fentanyl patches.
- Expansion of AVERSA™ technology to other medications indicates a scalable platform with broad applications.
- Subsidiaries 4P Therapeutics and Pocono Pharmaceutical provide additional revenue streams through research, development, and manufacturing services.
- An experienced leadership team with expertise in pharmaceutical development and transdermal technologies guides the company’s strategic initiatives.
Nutriband Inc. (NASDAQ: NTRB) is a U.S.-based pharmaceutical company specializing in the development of innovative transdermal drug delivery systems. The company’s core focus is to enhance patient outcomes by utilizing advanced drug delivery technologies, specifically targeting the global opioid epidemic. By integrating aversive agents into transdermal patches, Nutriband aims to prevent the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as fentanyl.
Nutriband’s mission is to improve patient safety and comfort by transforming new ideas and discoveries into safer pharmaceutical products. Through its proprietary AVERSA™ technology, the company seeks to set new safety standards for medications that are effective yet carry significant risks of abuse.
Recognizing the critical need for safer opioid medications, Nutriband is dedicated to developing solutions that address this public health crisis.
The company is headquartered in Orlando, Florida.
Products
Nutriband’s product portfolio centers around its proprietary AVERSA™ abuse-deterrent transdermal technology:
- AVERSA™ Fentanyl Transdermal System: This lead product incorporates AVERSA™ technology into an FDA-approved fentanyl patch, aiming to provide chronic pain relief while deterring abuse. The system is designed to prevent the extraction and misuse of fentanyl, addressing a significant contributor to opioid-related fatalities.
- Pipeline Products: The company is exploring the application of AVERSA™ technology to other transdermal products, including buprenorphine patches for chronic pain and opioid dependence, methylphenidate patches for attention deficit hyperactivity disorder (ADHD), and novel transdermal delivery systems for drugs like exenatide (type 2 diabetes) and follicle-stimulating hormone (infertility).
In addition to its proprietary products, Nutriband offers contract research and development services through its subsidiary, 4P Therapeutics, and contract manufacturing services for matrix-coated products, topicals, and cosmetics via Pocono Pharmaceutical.
Market Opportunity
The opioid epidemic remains a pressing public health issue, with opioid overdoses accounting for a significant number of deaths annually. The global market for abuse-deterrent formulations is expected to grow as regulatory bodies and healthcare providers seek solutions to mitigate this crisis. Nutriband’s AVERSA™ technology positions the company to address this need by offering safer transdermal delivery options for high-risk medications.
Furthermore, the transdermal drug delivery market is projected to expand, driven by the demand for non-invasive delivery methods that improve patient compliance and therapeutic outcomes. Nutriband’s expertise in this area allows it to capitalize on opportunities within both the opioid abuse deterrence and broader transdermal delivery markets.
Leadership Team
Gareth Sheridan, Founder and CEO, is an award-winning entrepreneur who established Nutriband Inc. He leads the company’s strategic direction and oversees its operations.
Dr. Jeff Patrick, Chief Scientific Officer, brings extensive experience in drug development and currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center.
Gerald Goodman, Chief Financial Officer, is a certified public accountant with a background in financial management and accounting.
Dr. Alan Smith, President of 4P Therapeutics, co-founded 4P Therapeutics and leads clinical, regulatory, quality, and operations at Nutriband.
Michael Myer, President of Pocono Pharmaceutical, has extensive knowledge and experience in the transdermal patch industry, focusing on building regulatory-compliant quality systems.